Astex Pharmaceuticals is pleased to share the below news which was today Issued by its collaborator The Institute of Cancer Research, London,
MHRA approves first-in-class breast cancer drug
• MHRA approves first-in-class drug Truqap (capivasertib) in combination with fulvestrant for treating HR-positive, HER-2 negative locally advanced breast cancer with specific biomarker alterations (PIK3CA, AKT1 or PTEN) alterations following recurrence or progression on or after an endocrine based regimen